1. Publication list ECAT Foundation

Publications #

1. Thompson SG, Duckert F, Haverkate F, Thomson JM. The measurement of haemostatic factors in 16 European laboratories: quality assessment for the Multicentre ECAT Angina Pectoris Study. Report from the European Concerted Action on Thrombosis and Disabilities (ECAT). Thromb Haemost. 1989;61:301-6.

2. Thompson SG, Calori G, Thomson JM, Haverkate F, Duckert F. The impact of sequential quality assessment exercises on laboratory performance: the multicentre ECAT Angina Pectoris Study. Report from the European Concerted Action on Thrombosis and Disabilities (ECAT). Thromb Haemost. 1991;65:149-52.

3. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost. 1999;81:929-34.

4. de Maat MP, Meijer P, Nieuwenhuizen W, Haverkate F, Kluft C. Performance of semiquantitative and quantitative D-dimer assays in the ECAT external quality assessment program. Semin Thromb Hemost. 2000;26:625-30.

5. Meijer P, de Maat MP, Kluft C, Haverkate F, van Houwelingen HC. Long-term analytical performance of hemostasis field methods as assessed by evaluation of the results of an external quality assessment program for antithrombin. Clin Chem. 2002;48:1011-5.

6. Meijer P, Kluft C, Haverkate F, De Maat MP. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation. J Thromb Haemost. 2003;1:748-53.

7. Meijer P. Method comparison: correlation is not enough to decide about agreement and clinical accuracy. Thromb Haemost. 2003;90:555-6.

8. Meijer P. Reply to Wood WG. Questionable results–who directs the EQAS organisers? A comment from the point of view of the ECAT Foundation. Clin Chem Lab Med. 2004;42:1081.

9. Meijer P, Haverkate F. External quality assessment and the laboratory diagnosis of thrombophilia. Semin Thromb Hemost. 2005;31:59-65.

10. Van Cott EM, Ledford-Kraemer M, Meijer P, Nichols WL, Johnson SM, PeerschkeEI; NASCOLA Proficiency Testing Committee. Protein S assays: an analysis of North American Specialized Coagulation Laboratory Association proficiency testing. Am J Clin Pathol. 2005;123:778-85.

11. Meijer P, Kluft C. The harmonization of quantitative test results of different D-dimer methods. Semin Vasc Med. 2005;5:321-7.

12. Spannagl M, Haverkate F, Reinauer H, Meijer P. The performance of quantitative D-dimer assays in laboratory routine. Blood Coagul Fibrinolysis. 2005;16:439-43.

13. Meijer P, Haverkate F, Kluft C, de Moerloose P, Verbruggen B, Spannagl M. A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost. 2006;95:567-72.

14. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost. 2006;32:485-91.

15. Meijer P, Haverkate F, Kluft C. Performance goals for the laboratory testing of antithrombin, protein C and protein S. Thromb Haemost. 2006;96:584-9.

16. Poller L, Keown M, Ibrahim SA, van der Meer FJ, van den Besselaar AM, Tripodi A, Jespersen J, Meijer P, Kluft C; European Concerted Action on Thrombosis. Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. Clin Chem. 2006;52:1843-7.

17. Meijer P, Kluft C, Poller L, van der Meer FJ, Keown M, Ibrahim S, van den Besselaar AM, Tripodi A, Jespersen J. A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. Am J Clin Pathol. 2006;126:756-61.

18. Verbruggen B, Meijer P, Novákova I, Van Heerde W. Diagnosis of factor VIII deficiency. Haemophilia. 2008;14 Suppl 3:76-82.

19. Moffat KA, Ledford-Kraemer MR, Plumhoff EA, McKay H, Nichols WL, Meijer P, Hayward CP. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost. 2009;101:178-84.

20. Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P; NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol. 2009;131:552-8.

21. Rudez G, Meijer P, Spronk HM, Leebeek FW, ten Cate H, Kluft C, de Maat MP. Biological variation in inflammatory and hemostatic markers. J Thromb Haemost. 2009;7:1247-55.

22. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost. 2009;35:786-93.

23. Kluft C, Meijer P. External quality assessment for thrombin generation tests: an exploration. Semin Thromb Hemost. 2010;36:791-6.

24. Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by north american clinical laboratories. Am J Clin Pathol. 2010;134:764-73.

25. Chandler WL, Peerschke EI, Castellone DD, Meijer P; NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol. 2011;135:862-9.

26. Stavelin A, Meijer P, Kitchen D, Sandberg S. External quality assessment of point-of-care International Normalized Ratio (INR) testing in Europe. Clin Chem Lab Med. 2011;50:81-8.

27. Verbruggen B, Dardikh M, Polenewen R, van Duren C, Meijer P. The factor VIII inhibitor assays can be standardized: results of a workshop. J Thromb Haemost. 2011;9:2003-8.

28. Meijer P. Clinically needed sensitivity for very low levels of Factor XIII: not yet proven for a new functional assay. Clin Chem Lab Med. 2011;49:1753-4.

29. Reber G, Meijer P. In ECAT veritas? Lupus. 2012;21:722-4.

30. Baron JM, Johnson SM, Ledford-Kraemer MR, Hayward CP, Meijer P, Van Cott EM. Protein C assay performance: an analysis of North American specialized coagulation laboratory association proficiency testing results. Am J Clin Pathol. 2012;137:909-15.

31. Kristoffersen AH, Thue G, Ajzner E, Claes N, Horvath AR, Leonetti R, Kallion K, Kitchen D, Kitchen S, Kutt M, Meijer P, Muller M, Nilsson E, Perich C, Plum I, Rogic D, Tirimacco R, van der Meer FJ, Watine J, Sandberg S. Interpretation and management of INR results: a case history based survey in 13 countries. Thromb Res. 2012;130:309-15.

32. Hayward CP, Moffat KA, Plumhoff E, Timleck M, Hoffman S, Spitzer E, Van Cott EM, Meijer P. External quality assessment of platelet disorder investigations: results of international surveys on diagnostic tests for dense granule deficiency and platelet aggregometry interpretation. Semin Thromb Hemost. 2012;38:622-31.

33. Dardikh M, Meijer P, van der Meer F, Favaloro EJ, Verbruggen B. Acquired functional coagulation inhibitors: review on epidemiology, results of a wet-workshop on laboratory detection, and implications for quality of inhibitor diagnosis. Semin Thromb Hemost. 2012;38:613-21.

34. Talens S, Malfliet JJ, Rudež G, Spronk HM, Janssen NA, Meijer P, Kluft C, de Maat MP, Rijken DC. Biological variation in tPA-induced plasma clot lysis time. Thromb Haemost. 2012;108:640-6.

35. Zantek ND, Hsu P, Refaai MA, Ledford-Kraemer M, Meijer P, Van Cott EM. Factor VII assay performance: an analysis of the North American Specialized Coagulation Laboratory Association proficiency testing results. Int J Lab Hematol. 2013;35:314-21.

36. Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G. Problems and solutions in laboratory testing for hemophilia. Semin Thromb Hemost. 2013;39:816-33.

37. Hsu P, Zantek ND, Meijer P, Hayward CP, Brody J, Zhang X, Smock KJ, Van Cott EM. Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of International Proficiency testing results. Semin Thromb Hemost. 2014;40:232-8.

38. Smock KJ, Ledford-Kraemer MR, Meijer P, Hsu P, Van Cott EM. Proficiency testing results for heparin-induced thrombocytopenia in north america. Semin Thromb Hemost. 2014;40:254-60.

39. Zantek ND, Hsu P, Meijer P, Smock KJ, Plumhoff EA, Refaai MA, Van Cott EM. Quality of factor XI activity testing in North American Specialized Coagulation Laboratories. Int J Lab Hematol. 2015;37 Suppl 1:99-107.

40. Ajzner É, Rogic D, Meijer P, Kristoffersen AH, Carraro P, Sozmen E, Faria AP, Sandberg S; joint Working Group on Postanalytical Phase (WG-POST) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM). An international study of how laboratories handle and evaluate patient samples after detecting an unexpected APTT prolongation. Clin Chem Lab Med. 2015;53:1593-603.

41. Kristoffersen AH, Ajzner E, Rogic D, Sozmen EY, Carraro P, Faria AP, Watine J, Meijer P, Sandberg S; joint Working Group on Postanalytical Phase (WG-POST) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM). Is D-dimer used according to clinical algorithms in the diagnostic work-up of patients with suspicion of venous thromboembolism? A study in six European countries. Thromb Res. 2016;142:1-7.

42. Smock KJ, Plumhoff EA, Meijer P, Hsu P, Zantek ND, Heikal NM, Van Cott EM.Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories. Thromb Haemost. 2016;116:50-7.

43. Van Cott EM, Smock KJ, Chen D, Hsu P, Zantek ND, Meijer P. Testing for dabigatran and rivaroxaban by clinical laboratories. Am J Hematol. 2016;91:E464-E467.

44. de Maat MP, van Schie M, Kluft C, Leebeek FW, Meijer P. Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications. Clin Chem. 2016;62:1639-1646.

45. De la Salle B, Meijer P, Thomas A, Simundic AM. Special issue on ExternalQ uality Assessment in Laboratory Medicine – current challenges and future trends. Biochem Med (Zagreb). 2017;27:19-22.

46. Kristensen GB, Meijer P. Interpretation of EQA results and EQA-based trouble shooting. Biochem Med (Zagreb). 2017;27:49-62.

47. Kristoffersen AH, Ajzner E, Bauça JM, Carraro P, Faria AP, Hillarp A, Rogic D, Sozmen EY, Watine J, Meijer P, Sandberg S. Pre- and post-test probabilities of venous thromboembolism and diagnostic accuracy of D-dimer, estimated by European clinicians working in emergency departments. Thromb Res. 2017;159:19-23.

48. Olson JD, Jennings I, Meijer P, Bon C, Bonar R, Favaloro EJ, Higgins RA, Keeney M, Mammen J, Marlar RA, Meley R, Nair SC, Nichols WL, Raby A, Reverter JC, Srivastava A, Walker I. Lack of grading agreement among international hemostasis external quality assessment programs. Blood Coagul Fibrinolysis. 2018;29:111-119.

49. Favaloro EJ, Bonar R, Hollestelle MJ, Jennings I, Mohammed S, Meijer P, Woods T, Meiring M. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study. Thromb Res. 2018;166:96-105.

50. Meijer P, Kynde K, van den Besselaar AMHP, Van Blerk M, Woods TAL. International normalized ratio (INR) testing in Europe: between-laboratory comparability of test results obtained by Quick and Owren reagents. Clin Chem Lab Med. 2018;56:1698-1703.

51. Ruhaak LR, Romijn FPHTM, Smit NPM, van der Laarse A, Pieterse MM, de Maat MPM, Haas FJLM, Kluft C, Amiral J, Meijer P, Cobbaert CM. Detecting molecular forms of antithrombin by LC-MRM-MS: defining the measurands. Clin Chem Lab Med. 2018;56:1704-1714.

52. Favaloro EJ, Jennings I, Olson J, Van Cott EM, Bonar R, Gosselin R, Meijer P. Towards harmonization of external quality assessment/proficiency testing in hemostasis. Clin Chem Lab Med. 2018;57:115-126.

53. van Moort I, Meijer P, Priem-Visser D, van Gammeren AJ, Péquériaux NCV, Leebeek FWG, Cnossen MH, de Maat MPM. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme. Haemophilia. 2019;25:162-169.

54. Liederman Z, Van Cott EM, Smock K, Meijer P, Selby R. Heparin-induced thrombocytopenia: An international assessment of the quality of laboratory testing. J Thromb Haemost. 2019;17:2123-2130

55. Kristoffersen AH, Stavelin AV, Ajzner E, Kristensen GBB, Sandberg S, Van Blerk M, Kitchen S, Kesseler D, Woods TAL, Meijer P. Pre-analytical practices for routine coagulation tests in European laboratories. A collaborative study from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM). Clin Chem Lab Med. 2019;57:1511-1521

56. Hayward CPM, Moffat KA, Brunet J, Carlino SA, Plumhoff E, Meijer P, Zehnder JL. Update on diagnostic testing for platelet function disorders: What is practical and useful? Int J Lab Hematol. 2019;41 Suppl 1:26-32

57. Hollestelle MJ, Ruinemans-Koerts J, Idema RN, Meijer P, de Maat MPM. Determination of sigma score based on biological variation for haemostasis assays: fit-for-purpose for daily practice? Clin Chem Lab Med. 2019;57:1235-1241

58. Hollestelle MJ, van der Meer FJM, Meijer P. Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data. Clin Chem Lab Med. 2020; 58:1921-1930.

59. Nederlof A, Kitchen S, Meijer P, Cnossen M, Ali Pour N, Kershaw G, Jennings I, Walker I, de Maat MPM. Performance of factor IX extended half-life product measurements in external quality control assessment programs. J Thromb Haemost. 2020;18:1874-1883.

60. Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R; Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. J Thromb Haemost. 2020;18:17-22.

61. Hollestelle MJ, Meijer P. International external quality assessment for measurements of direct oral anticoagulants: results and recommendations. Br J Haematol. 2020;188:460-464.

62. Abdulrehman, J., Y.C. Ziemba, P. Hsu, E.M. Van Cott, E.A. Plumhoff, P. Meijer, et al., Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories. Haemophilia, 2021; 27: e713-e720.

63. Arisz, R.A., P. Meijer, N.C.V. Pequeriaux, S.J. van de Leur, M.V. Lukens, M.P.M. de Maat, et al., Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories. Int J Lab Hematol, 2022; 44: 407-413.

64. Reilly-Stitt, C., I. Jennings, S. Kitchen, M. Makris, P. Meijer, M. de Maat, et al., Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. J Thromb Haemost, 2022; 20: 1875-1879.

65. Hollestelle, M.J., J.C.M. Meijers and P. Meijer, How Do Laboratories Perform von Willebrand Disease Diagnostics and Classification of von Willebrand Disease Patients? Results from External Quality Data and an International Survey. Semin Thromb Hemost, 2022; 48: 739-749.

66. Ziemba, Y.C., J. Abdulrehman, M.J. Hollestelle, P. Meijer, E. Plumhoff, P. Hsu, et al., Diagnostic Testing for von Willebrand Disease: Trends and Insights from North American Laboratories over the Last Decade. Semin Thromb Hemost, 2022:700–710.

67. Hollestelle, M. J., A. H. Kristoffersen, R. N. Idema, P. Meijer, et al. (2023). “Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands.” Clin Chem Lab Med 61(8): 1470-1480.